Actively Recruiting
Pavlik Harness Treatment vs Monitoring for Treatment of Developmental Dysplasia of the Hip (DDH) in Babies Diagnosed With Graf Type 2 Hips
Led by Maidstone & Tunbridge Wells NHS Trust · Updated on 2026-03-23
70
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
Sponsors
M
Maidstone & Tunbridge Wells NHS Trust
Lead Sponsor
C
Canterbury Christ Church University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Developmental Dysplasia of the Hip (DDH) is thoroughly manageable if treated correctly. While the standard treatment is using a Pavlik harness, there is not enough research regarding those patients who have stable but immature Graf type 2b and 2c hips and whether a harness is needed. At Maidstone and Tunbridge Wells NHS Trust, all babies who present with Graf type 2b and 2c hip dysplasia are treated using a Pavlik harness, which is worn 24 hours a day for up to 12 weeks. Although the harness is usually very comfortable, it can result in stress and anxiety for parents, and may make caregiving activities such as bathing, feeding and carrying more difficult. Our aim is to run a feasibility trial, recruiting babies with type 2b and 2c hip dysplasia, to determine whether there is any difference in a group which is treated with Pavlik harnessing, or whether these hips do in fact mature on their own. We would like to ensure that Pavlik harness treatment is indeed necessary in these groups. Babies randomised to the comparator group with type 2b and 2c hips would be treated using a Pavlik Harness and following the usual protocol with ultrasound scans at 3 weeks, 8 weeks and 12 weeks post start of treatment, and harness duration is determined by the scan at 8 weeks. Babies randomised to the Intervention group would be monitored via ultrasound scans at 3 weeks, 6 weeks, 8 weeks and 12 weeks post diagnosis, and should it be determined that their hips are not maturing spontaneously, they will be placed in a harness immediately, and follow the treatment-group protocol. Since the scans are done so frequently, and their hips are stable, there is no risk to these babies. Babies in both groups would have x-rays at 9 months and 15 months to determine longer-term outcome. The trial will last for 15 months after diagnosis for each patient, and the end-point of the study would be on achieving a 15-month x-ray for the last recruited patient. Patients will be informed of the results of the study.
CONDITIONS
Official Title
Pavlik Harness Treatment vs Monitoring for Treatment of Developmental Dysplasia of the Hip (DDH) in Babies Diagnosed With Graf Type 2 Hips
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infants from birth to 16 weeks with Graf type 2b or 2c hip dysplasia on ultrasound
You will not qualify if you...
- Associated neuromuscular, genetic or neurological condition which may complicate the course of treatment
- Babies who have unstable hips on clinical examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Maidstone and Tunbridge Wells NHS trust
Royal Tunbridge Wells, United Kingdom
Actively Recruiting
Research Team
N
Nicole Hilburn, PhD
CONTACT
J
Joanne Dartnell, Consultant Orthopaedic Surgeon
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here